molecular formula C19H24N4O2 B1679287 Pentamidine CAS No. 100-33-4

Pentamidine

Cat. No.: B1679287
CAS No.: 100-33-4
M. Wt: 340.4 g/mol
InChI Key: XDRYMKDFEDOLFX-UHFFFAOYSA-N
Attention: For research use only. Not for human or veterinary use.
In Stock
  • Click on QUICK INQUIRY to receive a quote from our team of experts.
  • With the quality product at a COMPETITIVE price, you can focus more on your research.

Description

Historical Context and Evolution of Pentamidine's Research Trajectory

The research journey of this compound is marked by its initial discovery as a treatment for tropical diseases and its later repurposing during a major global epidemic.

This compound first entered medical use in 1937. wikipedia.org Early research focused on its efficacy against parasitic protozoa. In 1937, it was first applied in the treatment of African trypanosomiasis, and by 1940, it was also being used for leishmaniasis. wikipedia.org These initial applications established this compound as a key agent in the limited chemotherapeutic arsenal against these neglected tropical diseases. researchgate.netplos.org The diamidine structure of the compound is considered essential for its antiparasitic activity, which is thought to be based primarily on its ability to bind to the parasite's DNA. asm.org

The research trajectory of this compound took a significant turn with the emergence of the HIV/AIDS epidemic in the early 1980s. A sudden increase in requests from the CDC for the then-unlicensed this compound isethionate to treat Pneumocystis jirovecii pneumonia (PCP), at the time known as Pneumocystis carinii pneumonia, in previously healthy young men was a key indicator in identifying the emerging epidemic. wikipedia.orgcdc.gov This led to a renewed research focus on the compound. Its efficacy against PCP was formally demonstrated in 1987, following its re-introduction to the market in 1984 as this compound isethionate. wikipedia.org this compound became a critical second-line therapy for PCP, particularly for patients who could not tolerate the first-line treatment, trimethoprim-sulfamethoxazole. droracle.aidrugs.com

Table 1.1: Key Milestones in this compound Research

YearMilestone
1937First used for the treatment of African trypanosomiasis. wikipedia.org
1940First used for the treatment of leishmaniasis. wikipedia.org
1950Registered as this compound mesylate. wikipedia.org
1981Increased requests for use in PCP cases signal the start of the AIDS epidemic. cdc.gov
1984Re-emerges on the market as this compound isethionate; approved for use in the U.S. wikipedia.orgnih.gov
1987Efficacy against Pneumocystis jirovecii is formally demonstrated. wikipedia.org

Initial Identification and Early Therapeutic Applications

Scope of this compound's Antiprotozoal and Antifungal Research

This compound has been the subject of extensive research for its activity against a range of pathogenic microorganisms, including protozoa and fungi. amegroups.org

Pneumocystis jirovecii pneumonia (PCP) is a life-threatening opportunistic infection, particularly in immunocompromised individuals. clinicaltrials.govnih.gov this compound has been a cornerstone of research for both the treatment and prevention of PCP. wikipedia.orgnih.gov

Research has explored various formulations and delivery methods. Intravenous (IV) this compound is approved for the treatment of PCP. ashpublications.org Studies have also investigated the use of IV this compound for prophylaxis, demonstrating its potential as a safe and feasible option for patients undergoing intensive chemotherapy or stem cell transplantation. clinicaltrials.govashpublications.org

Aerosolized this compound, administered via a nebulizer, was developed as an alternative for prophylaxis. drugs.comajtmh.org This route of administration delivers the drug directly to the lungs, achieving high concentrations in the bronchoalveolar fluid. wikipedia.org Research in HIV-positive patients has shown that nebulized this compound is an effective form of prophylaxis against PCP. oup.com Studies in pediatric oncology patients have also found both intravenous and inhaled this compound to be effective second-line alternatives for PCP prophylaxis. nih.gov

Table 1.2: Selected Research Findings on this compound for PCP Prophylaxis

Study PopulationFormulationKey FindingCitation
Adult Hematologic Malignancy/Stem Cell Transplant PatientsIntravenousNo cases of PJP were documented during a 12-month prospective study. ashpublications.org
Pediatric Oncology PatientsIntravenous & AerosolizedA retrospective review of 754 patients found no cases of probable or proven PJP. nih.gov
HIV-positive PatientsAerosolizedA study of 173 patients found only seven breakthrough episodes of PJP. oup.com

This compound is used to treat the early or first stage of West African trypanosomiasis caused by Trypanosoma brucei gambiense, before the central nervous system is involved. wikipedia.orgdrugs.commedscape.com It is considered a second-line option to suramin for this indication. wikipedia.org The drug is not effective for the neurological stage of the disease because it does not adequately cross the blood-brain barrier. medscape.com Research has confirmed its efficacy, with cure rates reported to be over 90% in the early stage of the disease. medscape.com Studies have also investigated optimized treatment regimens to improve patient adherence. isrctn.com A genome-wide screen identified an aquaglyceroporin, TbAQP2, as being required for high-affinity uptake of this compound into the trypanosome parasite, providing a focus for future drug design research. plos.org

This compound is an option for treating both visceral and cutaneous forms of leishmaniasis. wikipedia.orgpediatriconcall.com It has a long history in the treatment of this disease, though it is often considered a second-line therapy. researchgate.netpfizer.com

A systematic review including 88 studies found a pooled cure rate for tegumentary leishmaniasis of 78.8% in controlled randomized trials and 84.8% for visceral leishmaniasis in similar trials. nih.gov Research on cutaneous leishmaniasis caused by Leishmania guyanensis has shown varying efficacy. One pilot study of a single-dose regimen reported a 55% effectiveness rate. scielo.br For mucosal leishmaniasis caused by Leishmania braziliensis, a pilot study of aerosolized this compound found it cured 6 of 7 patients with initially mild disease. ajtmh.org Research has also explored its use in combination with other drugs, such as oral miltefosine, for mucosal leishmaniasis. clinicaltrials.gov

This compound has also been investigated as a secondary prophylactic agent to prevent relapses of visceral leishmaniasis in HIV-co-infected patients, a population at high risk for recurrence. dndi.org A study in Ethiopia found that monthly this compound prophylaxis resulted in a 29% failure rate within one year, a significant improvement over historical controls. dndi.orgplos.org

Research on Other Fungal Infections

While this compound is well-known for its role in managing Pneumocystis jirovecii pneumonia, extensive research has been conducted to evaluate its efficacy against a range of other pathogenic fungi. clinicaltrials.govresearchgate.net These investigations have unveiled a broad spectrum of antifungal activity, positioning this compound as a compound of interest for various mycoses.

Studies have demonstrated this compound's ability to suppress the growth of Candida species in both in vitro and in vivo models. wikipedia.org Research into its effects on Candida albicans has shown that concentrations of 10 mg/L or higher can inhibit the yeast's growth. wikipedia.org Furthermore, when combined with azole antifungals like itraconazole, this compound exhibits a fungicidal effect against a significant percentage of tested strains. wikipedia.org More recent research has focused on the formidable multidrug-resistant pathogen, Candida auris. Studies have reported that this compound alone shows fungicidal activity against C. auris, with Minimum Inhibitory Concentrations (MICs) ranging from 16 to 128 μg/mL. scienceopen.comspandidos-publications.com When used in combination with the anti-rheumatic drug auranofin, this compound demonstrates a synergistic and fungistatic effect, highlighting its potential in combination therapies for difficult-to-treat infections. scienceopen.comspandidos-publications.com The mechanism in this synergy involves this compound increasing the permeability of the fungal cell membrane, which enhances the uptake of auranofin. spandidos-publications.comscienceopen.com

The antifungal activity of this compound extends to Cryptococcus neoformans, a major cause of meningitis in immunocompromised individuals. In-vitro studies have shown that this compound at concentrations of 10 and 100 mg/L inhibits the growth of clinical isolates of C. neoformans from AIDS patients. wikipedia.org For most of these strains, MICs were found to be between 3.12 and 6.25 mg/L, with Minimum Fungicidal Concentrations (MFCs) ranging from 12.5 to over 100 mg/L. wikipedia.org this compound has also been shown to be effective against spore germination in Cryptococcus, suggesting a potential prophylactic role in preventing spore-mediated disease. medscape.com

Research has also explored the activity of this compound against filamentous fungi, such as Aspergillus species. In vitro testing of 70 Aspergillus strains, including A. fumigatus, A. flavus, and A. niger, revealed that this compound was active, particularly in yeast nitrogen base media. medicinacomplementar.com.brajtmh.org Given that some of these species can be refractory to standard treatments, this compound could represent a useful therapeutic alternative. ajtmh.org Additionally, selected analogues of this compound have demonstrated activity against Fusarium solani, another opportunistic mold. nih.gov

Table 1: In Vitro Antifungal Activity of this compound Against Various Fungal Pathogens


Fungal PathogenKey Research FindingObserved EffectCitations
Candida albicansInhibitory effect at concentrations ≥ 10 mg/L.Inhibitory/Fungicidal (with azoles) wikipedia.org
Candida aurisMICs ranged from 16 to 128 μg/mL. Synergistic effect with auranofin.Fungicidal/Fungistatic (with auranofin)[5, 7]
Cryptococcus neoformansMICs for most strains ranged from 3.12 to 6.25 mg/L.Inhibitory/Fungicidal wikipedia.org
Aspergillus speciesDemonstrated in vitro activity against various species including A. fumigatus.Inhibitory[11, 12]
Fusarium solaniAnalogues of this compound showed activity against this species.Inhibitory[2, 4]

Emerging Research Areas and Repurposing Potential

The established use of this compound as an antiprotozoal agent for treating diseases like leishmaniasis and African trypanosomiasis has provided a foundation for exploring its repurposing for other therapeutic applications. wikipedia.orgmedscape.comnih.gov Its ability to interfere with fundamental cellular processes such as DNA, RNA, and protein synthesis has made it an attractive candidate for investigation in oncology and other areas beyond its original indications. wikipedia.orgdrugbank.com

A significant area of emerging research is the repurposing of this compound for cancer therapy. scienceopen.com Studies have identified it as a small-molecule antagonist of the programmed death-ligand 1 (PD-L1). scienceopen.com By binding to PD-L1, this compound can block the PD-1/PD-L1 interaction, which is a key immune checkpoint pathway that cancer cells exploit to evade the immune system. scienceopen.com This action enhances T-cell-mediated cytotoxicity against cancer cells, as evidenced by increased secretion of interferon-gamma (IFN-γ), tumor necrosis factor-alpha (TNF-α), perforin, and granzyme B. In vivo studies with murine tumor models have shown that this compound administration can reduce tumor growth and increase the number of tumor-infiltrating lymphocytes. scienceopen.com

Further research into its anticancer mechanisms has revealed that this compound can also inhibit the S100B-p53 protein-protein interaction, which is thought to restore the tumor suppressor function of wild-type p53 in cancers like melanoma. spandidos-publications.commedicinacomplementar.com.br Other proposed mechanisms include the inhibition of the PRL (phosphatase of regenerating liver) family of phosphatases, which are overexpressed in many cancers and play a role in cell cycle progression. medicinacomplementar.com.brptfarm.pl Clinical trials have been initiated to evaluate this compound in various cancer types, including melanoma, classical Hodgkin lymphoma, and pancreatic cancer, often in combination with standard chemotherapy regimens. clinicaltrials.govclinicaltrials.govcancer.govmedpath.com

Beyond oncology, research has identified this compound as a potential prophylactic agent against sexually transmitted infections. A recent study found that it can prevent Chlamydia trachomatis infection in mouse models and also inhibits the growth of Neisseria gonorrhoeae, the bacterium that causes gonorrhea. news-medical.net The proposed mechanism involves the suppression of host cell metabolism, which these intracellular bacteria require for their growth. news-medical.net Additionally, in the context of viral diseases, this compound has been identified as a potential blocker of the SARS-CoV-2 3a channel, suggesting a possible role in antiviral therapy that warrants further investigation. benthamdirect.com The development of nanocarrier drug delivery systems for this compound is also an active area of research, aiming to enhance its therapeutic efficacy and reduce systemic toxicity. scienceopen.comnih.gov

Table 2: Emerging and Repurposed Applications of this compound


Research AreaProposed Mechanism/TargetPotential ApplicationCitations
Cancer ImmunotherapyPD-L1 antagonist, blocking the PD-1/PD-L1 interaction.Enhancement of anti-tumor immune response.[2, 5]
Melanoma TherapyInhibition of S100B-p53 interaction, restoring p53 function.Treatment of relapsed or refractory melanoma.[11, 16]
General OncologyInhibition of PRL family phosphatases.Inhibition of cancer cell cycle progression.[11, 13]
Hodgkin LymphomaCombination therapy with salvage chemotherapy (ICE).Treatment for relapsed/refractory classical Hodgkin lymphoma. benthamdirect.com
Bacterial InfectionsInhibition of host cell metabolism required for bacterial growth.Prophylaxis for Chlamydia trachomatis and Neisseria gonorrhoeae.
Antiviral ResearchBlocker of the SARS-CoV-2 3a channel.Potential treatment for COVID-19.
LeishmaniasisDisruption of mitochondrial function in the parasite.Treatment for cutaneous and visceral leishmaniasis.[12, 14, 21, 22]
African TrypanosomiasisInterference with DNA biosynthesis in the parasite.Treatment for the hemolymphatic stage of sleeping sickness.[3, 4, 6]

Properties

IUPAC Name

4-[5-(4-carbamimidoylphenoxy)pentoxy]benzenecarboximidamide
Source PubChem
URL https://pubchem.ncbi.nlm.nih.gov
Description Data deposited in or computed by PubChem

InChI

InChI=1S/C19H24N4O2/c20-18(21)14-4-8-16(9-5-14)24-12-2-1-3-13-25-17-10-6-15(7-11-17)19(22)23/h4-11H,1-3,12-13H2,(H3,20,21)(H3,22,23)
Source PubChem
URL https://pubchem.ncbi.nlm.nih.gov
Description Data deposited in or computed by PubChem

InChI Key

XDRYMKDFEDOLFX-UHFFFAOYSA-N
Source PubChem
URL https://pubchem.ncbi.nlm.nih.gov
Description Data deposited in or computed by PubChem

Canonical SMILES

C1=CC(=CC=C1C(=N)N)OCCCCCOC2=CC=C(C=C2)C(=N)N
Source PubChem
URL https://pubchem.ncbi.nlm.nih.gov
Description Data deposited in or computed by PubChem

Molecular Formula

C19H24N4O2
Source PubChem
URL https://pubchem.ncbi.nlm.nih.gov
Description Data deposited in or computed by PubChem

DSSTOX Substance ID

DTXSID7023431
Record name Pentamidine
Source EPA DSSTox
URL https://comptox.epa.gov/dashboard/DTXSID7023431
Description DSSTox provides a high quality public chemistry resource for supporting improved predictive toxicology.

Molecular Weight

340.4 g/mol
Source PubChem
URL https://pubchem.ncbi.nlm.nih.gov
Description Data deposited in or computed by PubChem

Physical Description

Solid
Record name Pentamidine
Source Human Metabolome Database (HMDB)
URL http://www.hmdb.ca/metabolites/HMDB0014876
Description The Human Metabolome Database (HMDB) is a freely available electronic database containing detailed information about small molecule metabolites found in the human body.
Explanation HMDB is offered to the public as a freely available resource. Use and re-distribution of the data, in whole or in part, for commercial purposes requires explicit permission of the authors and explicit acknowledgment of the source material (HMDB) and the original publication (see the HMDB citing page). We ask that users who download significant portions of the database cite the HMDB paper in any resulting publications.

Solubility

Complete, Mol wt: 592.69. Hygroscopic, very bitter crystals, mp approx 180 °C. Slight butyric odor. Sol in water (approx 1 in 10 at 25 °C, approx 1 in 4 at 100 °C); sol in glycerol, more readily on warming; slightly sol in alcohol. Insol in ether, acetone, chloroform, liq petr. pH of a 5% w/v soln in water: 4.5 to 6.5. /Isethioante/, 2.36e-02 g/L
Record name Pentamidine
Source DrugBank
URL https://www.drugbank.ca/drugs/DB00738
Description The DrugBank database is a unique bioinformatics and cheminformatics resource that combines detailed drug (i.e. chemical, pharmacological and pharmaceutical) data with comprehensive drug target (i.e. sequence, structure, and pathway) information.
Explanation Creative Common's Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/legalcode)
Record name PENTAMIDINE
Source Hazardous Substances Data Bank (HSDB)
URL https://pubchem.ncbi.nlm.nih.gov/source/hsdb/7474
Description The Hazardous Substances Data Bank (HSDB) is a toxicology database that focuses on the toxicology of potentially hazardous chemicals. It provides information on human exposure, industrial hygiene, emergency handling procedures, environmental fate, regulatory requirements, nanomaterials, and related areas. The information in HSDB has been assessed by a Scientific Review Panel.
Record name Pentamidine
Source Human Metabolome Database (HMDB)
URL http://www.hmdb.ca/metabolites/HMDB0014876
Description The Human Metabolome Database (HMDB) is a freely available electronic database containing detailed information about small molecule metabolites found in the human body.
Explanation HMDB is offered to the public as a freely available resource. Use and re-distribution of the data, in whole or in part, for commercial purposes requires explicit permission of the authors and explicit acknowledgment of the source material (HMDB) and the original publication (see the HMDB citing page). We ask that users who download significant portions of the database cite the HMDB paper in any resulting publications.

Color/Form

Crystallizes as colorless plates from water

CAS No.

100-33-4
Record name Pentamidine
Source CAS Common Chemistry
URL https://commonchemistry.cas.org/detail?cas_rn=100-33-4
Description CAS Common Chemistry is an open community resource for accessing chemical information. Nearly 500,000 chemical substances from CAS REGISTRY cover areas of community interest, including common and frequently regulated chemicals, and those relevant to high school and undergraduate chemistry classes. This chemical information, curated by our expert scientists, is provided in alignment with our mission as a division of the American Chemical Society.
Explanation The data from CAS Common Chemistry is provided under a CC-BY-NC 4.0 license, unless otherwise stated.
Record name Pentamidine [INN:BAN:DCF]
Source ChemIDplus
URL https://pubchem.ncbi.nlm.nih.gov/substance/?source=chemidplus&sourceid=0000100334
Description ChemIDplus is a free, web search system that provides access to the structure and nomenclature authority files used for the identification of chemical substances cited in National Library of Medicine (NLM) databases, including the TOXNET system.
Record name Pentamidine
Source DrugBank
URL https://www.drugbank.ca/drugs/DB00738
Description The DrugBank database is a unique bioinformatics and cheminformatics resource that combines detailed drug (i.e. chemical, pharmacological and pharmaceutical) data with comprehensive drug target (i.e. sequence, structure, and pathway) information.
Explanation Creative Common's Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/legalcode)
Record name pentamidine
Source DTP/NCI
URL https://dtp.cancer.gov/dtpstandard/servlet/dwindex?searchtype=NSC&outputformat=html&searchlist=9921
Description The NCI Development Therapeutics Program (DTP) provides services and resources to the academic and private-sector research communities worldwide to facilitate the discovery and development of new cancer therapeutic agents.
Explanation Unless otherwise indicated, all text within NCI products is free of copyright and may be reused without our permission. Credit the National Cancer Institute as the source.
Record name Pentamidine
Source EPA DSSTox
URL https://comptox.epa.gov/dashboard/DTXSID7023431
Description DSSTox provides a high quality public chemistry resource for supporting improved predictive toxicology.
Record name Pentamidine
Source European Chemicals Agency (ECHA)
URL https://echa.europa.eu/substance-information/-/substanceinfo/100.002.583
Description The European Chemicals Agency (ECHA) is an agency of the European Union which is the driving force among regulatory authorities in implementing the EU's groundbreaking chemicals legislation for the benefit of human health and the environment as well as for innovation and competitiveness.
Explanation Use of the information, documents and data from the ECHA website is subject to the terms and conditions of this Legal Notice, and subject to other binding limitations provided for under applicable law, the information, documents and data made available on the ECHA website may be reproduced, distributed and/or used, totally or in part, for non-commercial purposes provided that ECHA is acknowledged as the source: "Source: European Chemicals Agency, http://echa.europa.eu/". Such acknowledgement must be included in each copy of the material. ECHA permits and encourages organisations and individuals to create links to the ECHA website under the following cumulative conditions: Links can only be made to webpages that provide a link to the Legal Notice page.
Record name PENTAMIDINE
Source FDA Global Substance Registration System (GSRS)
URL https://gsrs.ncats.nih.gov/ginas/app/beta/substances/673LC5J4LQ
Description The FDA Global Substance Registration System (GSRS) enables the efficient and accurate exchange of information on what substances are in regulated products. Instead of relying on names, which vary across regulatory domains, countries, and regions, the GSRS knowledge base makes it possible for substances to be defined by standardized, scientific descriptions.
Explanation Unless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required.
Record name PENTAMIDINE
Source Hazardous Substances Data Bank (HSDB)
URL https://pubchem.ncbi.nlm.nih.gov/source/hsdb/7474
Description The Hazardous Substances Data Bank (HSDB) is a toxicology database that focuses on the toxicology of potentially hazardous chemicals. It provides information on human exposure, industrial hygiene, emergency handling procedures, environmental fate, regulatory requirements, nanomaterials, and related areas. The information in HSDB has been assessed by a Scientific Review Panel.
Record name Pentamidine
Source Human Metabolome Database (HMDB)
URL http://www.hmdb.ca/metabolites/HMDB0014876
Description The Human Metabolome Database (HMDB) is a freely available electronic database containing detailed information about small molecule metabolites found in the human body.
Explanation HMDB is offered to the public as a freely available resource. Use and re-distribution of the data, in whole or in part, for commercial purposes requires explicit permission of the authors and explicit acknowledgment of the source material (HMDB) and the original publication (see the HMDB citing page). We ask that users who download significant portions of the database cite the HMDB paper in any resulting publications.

Melting Point

Decomposes at 186 °C, 186.0 °C (decomposes)
Record name Pentamidine
Source DrugBank
URL https://www.drugbank.ca/drugs/DB00738
Description The DrugBank database is a unique bioinformatics and cheminformatics resource that combines detailed drug (i.e. chemical, pharmacological and pharmaceutical) data with comprehensive drug target (i.e. sequence, structure, and pathway) information.
Explanation Creative Common's Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/legalcode)
Record name PENTAMIDINE
Source Hazardous Substances Data Bank (HSDB)
URL https://pubchem.ncbi.nlm.nih.gov/source/hsdb/7474
Description The Hazardous Substances Data Bank (HSDB) is a toxicology database that focuses on the toxicology of potentially hazardous chemicals. It provides information on human exposure, industrial hygiene, emergency handling procedures, environmental fate, regulatory requirements, nanomaterials, and related areas. The information in HSDB has been assessed by a Scientific Review Panel.
Record name Pentamidine
Source Human Metabolome Database (HMDB)
URL http://www.hmdb.ca/metabolites/HMDB0014876
Description The Human Metabolome Database (HMDB) is a freely available electronic database containing detailed information about small molecule metabolites found in the human body.
Explanation HMDB is offered to the public as a freely available resource. Use and re-distribution of the data, in whole or in part, for commercial purposes requires explicit permission of the authors and explicit acknowledgment of the source material (HMDB) and the original publication (see the HMDB citing page). We ask that users who download significant portions of the database cite the HMDB paper in any resulting publications.

Mechanistic Investigations of Pentamidine's Biological Actions

Resistance Mechanisms and Evolution in Pathogens

The emergence of drug resistance poses a significant challenge to the effective treatment of infectious diseases, including those targeted by pentamidine. Understanding the mechanisms by which pathogens develop resistance is crucial for developing new therapeutic strategies and preserving the efficacy of existing drugs. Resistance to this compound primarily involves mechanisms that reduce the intracellular accumulation of the drug, often leading to cross-resistance with other compounds. nih.govmdpi.comcapes.gov.br

Mechanisms of Reduced Drug Uptake

Reduced drug uptake is a prominent mechanism of this compound resistance across various pathogens.

In African trypanosomes (Trypanosoma brucei), resistance to this compound is frequently linked to alterations in specific membrane transporters. The high-affinity this compound transport (HAPT1) activity is notably absent in this compound-adapted trypanosome lines. nih.gov While the P2 aminopurine transporter, encoded by the TbAT1 gene, was initially implicated in diamidine uptake and resistance, its loss results in only a modest decrease in this compound sensitivity and is not the primary cause of clinical treatment failure. mdpi.com More critically, the aquaglyceroporin 2 (TbAQP2) has been identified as a key determinant of this compound sensitivity and resistance. mdpi.com In resistant strains, the wild-type TbAQP2 gene may be absent or replaced by a chimeric protein formed through recombination with parts of the closely related TbAQP3 gene. The expression of a wild-type copy of TbAQP2 can fully reverse the resistance phenotype. In contrast, the low affinity this compound transport (LAPT1) activity often remains unchanged in these resistant lines. nih.gov These changes ultimately lead to a reduced accumulation of this compound inside the trypanosome cell. mdpi.com

In Leishmania species (Leishmania mexicana), this compound-resistant parasites exhibit a substantial decrease in drug accumulation. nih.govresearchgate.netasm.org Although the apparent affinity (Km) of the carrier for this compound is not altered, the apparent maximal velocity (Vmax) of uptake is reduced. nih.govresearchgate.netasm.org Furthermore, resistant Leishmania cells demonstrate an increased efflux of this compound, meaning a larger proportion of the accumulated drug is released compared to wild-type cells. nih.govresearchgate.netasm.org This resistance phenotype is also accompanied by a lack of mitochondrial accumulation of the drug and its exclusion from the parasite's mitochondrion, potentially linked to a reduced mitochondrial membrane potential observed in resistant cells. nih.govresearchgate.net

The table below illustrates the difference in intracellular this compound accumulation between wild-type and resistant Leishmania mexicana promastigotes:

Strain TypeIntracellular this compound Concentration (µM) after 3hSource
Wild-type55 nih.gov
Pentr2.510 nih.gov
Pentr59 nih.gov
Pentr107 nih.gov
Pentr305 nih.gov

In Acinetobacter baumannii , a bacterium, this compound resistance can be influenced by the AdeAB efflux system, which is regulated by the AdeRS two-component signal transduction system. plos.org Deletion of the adeRS genes has been shown to result in an 8-fold decrease in this compound resistance. plos.org The mechanism of this compound action in Gram-negative bacteria is thought to primarily involve binding to the lipid-A component of the outer membrane, rather than an intracellular target. plos.orgbiorxiv.org Additionally, growth conditions, such as the availability of different carbon sources or iron levels, can significantly alter the this compound resistance profile in A. baumannii. plos.orgbiorxiv.org

Alterations in Drug Target Sites

For this compound, resistance is predominantly associated with mechanisms that prevent the drug from reaching its intracellular targets, rather than direct alterations or mutations in the target sites themselves. mdpi.com In Trypanosoma parasites, this compound is known to bind to adenine-thymine-rich regions of DNA and inhibit mitochondrial topoisomerase enzymes. wikipedia.org However, the observed resistance largely stems from impaired drug uptake and accumulation, preventing sufficient concentrations of the drug from reaching these targets. mdpi.com Similarly, in Acinetobacter baumannii, this compound's primary interaction is believed to be with the outer membrane's lipid-A component, suggesting that resistance mechanisms in this context would likely involve changes to membrane integrity or efflux rather than modifications to an enzymatic target. plos.orgbiorxiv.org

Pharmacokinetic and Pharmacodynamic Research

Absorption and Distribution Studies

Systemic Absorption Patterns

Pentamidine demonstrates varied absorption patterns depending on the route of administration. Following intravenous or intramuscular injection, the drug is well and completely absorbed. wikipedia.orgunboundmedicine.com In contrast, systemic absorption after inhalation is minimal. unboundmedicine.comnih.govpogo.ca Studies have shown that plasma concentrations after aerosol administration are significantly lower, approximately 5% to 10% of those achieved with equivalent parenteral doses. medsafe.govt.nznih.gov Specifically, one study noted that peak plasma levels in AIDS patients receiving aerosolized this compound were at or below the lower limit of detection (2.3 ng/mL). drugs.com Another study with AIDS patients reported average peak plasma levels of 18.8 ± 11.9 ng/mL after the first aerosol dose. drugs.com

Oral administration of this compound results in unreliable absorption. wikipedia.org

A comparison of pharmacokinetic parameters following a single 4 mg/kg dose in AIDS patients revealed significant differences between intramuscular and intravenous routes. hres.ca

Interactive Table: this compound Pharmacokinetic Parameters

Parameter Intramuscular Administration (4 mg/kg) Intravenous Administration (4 mg/kg, 2-hour infusion)
Mean Peak Plasma Concentration (Cmax) 209 ng/mL 612 ng/mL
Mean Plasma Clearance 305 L/h 248 L/h
Mean Elimination Half-Life 9.36 hours 6.40 hours
Mean Apparent Volume of Distribution 924 liters 140 liters
Mean Apparent Volume at Steady State 2,724 liters 821 liters

Tissue and Organ Concentration Profiles

This compound is extensively distributed throughout the body and tends to bind to tissues and plasma proteins. wikipedia.orgunboundmedicine.com It concentrates in several organs, notably the liver, kidneys, lungs, spleen, pancreas, and adrenal glands. wikipedia.orgunboundmedicine.compfizer.commims.com Research in animal models provides more specific details on this distribution.

In mice that received a single intraperitoneal injection of this compound, the highest concentrations were found in the kidneys, followed by the liver. drugs.comfda.gov Studies in dogs given intravenous this compound showed the highest concentration in the liver, followed by the kidneys and lungs. drugs.com The concentration of this compound in these organs was approximately 70 to 1000 times that of the peak serum concentration. drugs.com After repeated daily doses in dogs, the organs exhibited a further 3 to 7-fold accumulation, while serum concentrations did not change. drugs.com

Autoradiographic studies in rats after intravenous administration also demonstrated high concentrations in the kidneys, spleen, and bone marrow. nih.gov Notably, this compound does not effectively cross the blood-brain barrier to reach curative levels in the cerebrospinal fluid. wikipedia.orgnih.gov

Inhaled this compound results in high concentrations in the bronchoalveolar lavage fluid and sediment of the lungs, with minimal systemic distribution. wikipedia.orgnih.govdrugs.com A study in rats found that intravenous administration led to 87.5-fold and 62.3-fold higher concentrations in the liver and kidney, respectively, compared to aerosol administration. drugs.com

Intracellular Distribution within Pathogens

The selective action of this compound against certain protozoan pathogens is largely due to its selective accumulation within the pathogen rather than the host cell. researchgate.netnih.gov The drug's uptake is mediated by specific transporters on the pathogen's cell surface. researchgate.netnih.govlstmed.ac.uk

In Trypanosoma brucei, the causative agent of African trypanosomiasis, this compound is taken up by several transporters, including the P2 aminopurine transporter, the high-affinity this compound transporter (HAPT1), and the low-affinity this compound transporter (LAPT1). researchgate.netmdpi.com Once inside the trypanosome, this compound can accumulate to millimolar concentrations and is known to associate with the kinetoplast and nuclear DNA. mdpi.com Fluorescent analogues of this compound have been observed to rapidly illuminate the kinetoplast. mdpi.com Some research suggests that this compound uptake in trypanosomes might occur via endocytosis, with the aquaglyceroporin TbAQP2 acting as a high-affinity receptor. plos.org

In Leishmania species, this compound is taken up by a high-affinity transporter, likely a proton symporter. researchgate.net Following uptake into the cytoplasm, it is further concentrated within the mitochondrion. researchgate.netnih.gov Resistance to this compound in Leishmania mexicana has been linked to the exclusion of the drug from the mitochondrion. nih.govasm.org The ABC transporter PRP1 has also been implicated in conferring this compound resistance in Leishmania amastigotes. nih.gov

Elimination and Excretion Pathways

Renal Excretion Mechanisms and Saturable Transport

The kidneys are the primary route of elimination for this compound, with the drug being excreted largely unchanged in the urine. unboundmedicine.commims.comdrugs.comfda.gov Studies in mice have shown that the ratio of urinary to fecal excretion is approximately 4:1. drugs.comfda.gov

Research using isolated perfused rat kidneys has revealed that the renal transport of this compound is a complex process involving a combination of glomerular filtration, active tubular secretion, and passive reabsorption. oup.comnih.gov Evidence for active secretion comes from studies where co-administration of tetraethylammonium, an organic cation, significantly reduced the renal clearance of this compound. oup.comnih.gov

The excretion of this compound demonstrates non-linear kinetics, suggestive of a saturable transport mechanism. oup.comnih.gov At higher doses, the tubular transport system can become saturated, leading to decreased urinary excretion and increased accumulation of the drug in the kidney. oup.comnih.gov This saturation of luminal transport is a key factor contributing to the nephrotoxic potential of this compound. oup.comnih.gov Furthermore, this compound itself can inhibit the reabsorption of sodium in the distal nephron by blocking apical sodium channels, which can lead to hyperkalemia. nih.gov Limited data suggests that this compound is not significantly removed by hemodialysis or peritoneal dialysis. hres.capfizer.com

Long Terminal Half-Life and Drug Persistence

This compound exhibits a biphasic decline in plasma concentrations following administration. hres.capfizer.com An initial rapid distribution phase is followed by a much slower terminal elimination phase. pfizer.com The terminal elimination half-life has been reported to range from approximately 6.4 to 12 days following intravenous administration. pfizer.comdrugs.com Intramuscular administration can result in a half-life of around 7 to 11 hours. wikipedia.orgmims.com This long terminal half-life is indicative of a deep peripheral compartment where the drug is stored and slowly released. drugs.com

The persistence of this compound in the body is notable. The drug can be detected in the urine for six to eight weeks after therapy has ceased. hres.caoup.com This prolonged presence is due to its accumulation and slow elimination from tissue reservoirs, such as the liver and kidneys. pfizer.comnih.gov Studies in patients with impaired renal function have not found a strong correlation between creatinine clearance and plasma clearance or elimination half-life, although the half-life may be prolonged in severe renal impairment. pfizer.comnih.gov

Following inhalation, the pulmonary half-life is also very long, with the drug being detectable in bronchoalveolar lavage fluid for over 10 to 14 days, and in some cases up to 115 days after treatment completion. medsafe.govt.nznih.govnih.gov

Drug Accumulation with Multiple Dosing

Repeated administration of this compound leads to significant drug accumulation in the body, even in individuals with normal renal function. nih.govpdr.net This accumulation is a critical factor in both the therapeutic efficacy and the potential for toxicity associated with the drug. nih.gov

Studies have demonstrated that with multiple dosing, trough plasma concentrations of this compound increase. nih.gov In one study involving patients who had received prior doses, trough plasma concentrations ranged from 4.3 to 67.5 ng/mL, with a mean of 28.4 ± 26.6 ng/mL, indicating drug accumulation. nih.gov Another study in seven patients receiving daily intramuscular doses of 4 mg/kg for 10 to 12 days showed that plasma concentrations were maintained between 300 to 500 ng/mL and did not significantly change over time after injection or from one day to the next. drugs.com

The extent of accumulation can be influenced by several factors, including the dosage regimen and the patient's renal function. diabetesjournals.org Research has shown a correlation between the number of previous doses and the estimated elimination half-life, suggesting that with more doses, the drug is eliminated more slowly, contributing to its accumulation. nih.gov This accumulation is a determining risk factor for this compound-induced side effects, particularly glucose homeostasis disorders. diabetesjournals.org

The accumulation of this compound is not limited to parenteral administration. Following chronic inhalation therapy, the extent of this compound accumulation and its distribution are not fully known, which necessitates close monitoring of patients. drugs.comfda.gov After 14 days of repeated inhaled doses, the highest observed average maximum concentration (Cmax) was 20.5 ± 21.2 ng/mL. drugs.com In a separate study with daily inhaled administration for 21 days, the mean plasma levels shortly after the final dose were 11.8 ± 10.0 ng/mL. drugs.comfda.gov Although plasma concentrations after aerosol administration are considerably lower than after intravenous administration, the potential for systemic accumulation still exists. drugs.comfda.gov

The following table provides a summary of this compound accumulation data from various studies:

Table 1: this compound Accumulation with Multiple Dosing
Population/Study Design Dosing Regimen Key Findings Reference(s)
Patients with prior this compound doses Not specified Trough plasma concentrations ranged from 4.3 to 67.5 ng/mL, suggesting accumulation. nih.gov
7 patients receiving daily IM injections 4 mg/kg for 10-12 days Plasma concentrations maintained between 300-500 ng/mL. drugs.com
Patients on repeated dosing Not specified Increased trough concentrations and drug accumulation observed. nih.gov
11 patients on daily inhaled therapy 600 mg for 21 days Mean plasma levels averaged 11.8 ± 10.0 ng/mL after the 21st dose. drugs.comfda.gov
Patients on repeated inhaled therapy Not specified After 14 days, highest observed Cmax averaged 20.5 ± 21.2 ng/mL. drugs.com

Pharmacokinetic Modeling and Simulation

Pharmacokinetic modeling and simulation are valuable tools for understanding and predicting the behavior of this compound in the body. These models help in characterizing its absorption, distribution, metabolism, and excretion (ADME) properties, which are essential for optimizing dosing strategies. nih.gov

Studies have employed various models to describe the pharmacokinetics of this compound. A one-compartmental population pharmacokinetic model has been reported, which is consistent with the drug's limited distribution and protein binding. nih.gov However, other reports suggest a more complex disposition, with terminal half-lives ranging from 2.8 to 12 days, indicative of a deep peripheral compartment. drugs.com This suggests that a multi-compartment model may be more appropriate to fully capture the drug's distribution and elimination phases.

Simulations based on these models can be used to predict drug exposure under different physiological conditions and in special patient populations. nih.govliu.edu For instance, pharmacokinetic modeling can help in adjusting dosages for patients with renal impairment to avoid potential toxicity due to drug accumulation. liu.edu

Research has also utilized molecular modeling to investigate the interactions of this compound at a molecular level, which can provide insights into its mechanism of action and potential for drug interactions. rsc.org These simulations can help in understanding the factors that influence the binding of this compound to its targets and how structural modifications might affect its activity and selectivity. rsc.org

The development of physiologically-based pharmacokinetic (PBPK) models, which integrate physiological and anatomical data with the drug's physicochemical properties, offers a more comprehensive approach to predicting this compound's pharmacokinetics. nih.gov While specific PBPK models for this compound are not extensively detailed in the provided results, the application of such models to other drugs, like miltefosine, highlights their potential utility in optimizing antiprotozoal therapies. nih.gov

The table below summarizes key pharmacokinetic parameters of this compound that are used in modeling and simulation:

Table 2: Key Pharmacokinetic Parameters of this compound for Modeling
Parameter Value Route of Administration Reference(s)
Mean Peak Concentration (Cmax) 612 ± 371 ng/mL 4 mg/kg IV infusion (2-hour) drugs.comhres.cahres.ca
209 ± 48 ng/mL 4 mg/kg IM drugs.comhres.cahres.ca
Clearance 248 ± 91 L/h IV drugs.comhres.ca
305 ± 81 L/h IM drugs.comhres.ca
Elimination Half-life 6.4 ± 1.3 hours IV drugs.comhres.ca
9.4 ± 2.0 hours IM drugs.comhres.ca
Volume of Distribution (Vdss) 821 ± 535 L IV drugs.comhres.ca
2724 ± 1066 L IM drugs.comhres.ca

Structure-activity Relationship Sar Studies and Analogue Development

Design and Synthesis of Novel Pentamidine Analogues

The design of new this compound analogues is a strategic process aimed at optimizing the drug's therapeutic index. This involves chemical synthesis to create a library of related compounds, which are then evaluated for their biological activity. The primary goals are to increase potency against target organisms, broaden the spectrum of activity, and reduce adverse effects on host cells. nih.govresearchgate.net

Modifications of Aromatic Rings and Linkers

Researchers have extensively investigated the impact of altering the aromatic rings and the central linker of the this compound scaffold. researchgate.netnih.gov Modifications to the aromatic rings, such as the introduction of substituents or their replacement with different aromatic systems, can influence the molecule's electronic properties and its interaction with biological targets. nih.gov

The nature and length of the linker connecting the two aromatic moieties are critical determinants of the molecule's conformation and flexibility, which in turn affect its binding affinity to DNA and other cellular components. irb.hrwhiterose.ac.ukelifesciences.org Studies have explored a variety of linkers, including alkanediamides and those containing heteroatoms like oxygen, nitrogen, and sulfur. researchgate.netnih.gov For instance, replacing the pentane chain with a 1,4-piperazinediyl or a 1,3-phenylenediamide moiety has yielded compounds with increased activity against Pneumocystis carinii and reduced toxicity compared to this compound. researchgate.net The introduction of amide or secondary amine groups into the linker was explored to enhance protein-ligand interactions by providing both hydrogen bond donors and acceptors. whiterose.ac.uk

A key finding is that the linker's length and composition are strong determinants of high-affinity binding. elifesciences.org For example, analogues with a linker of 5-7 methylene units displayed submicromolar binding affinities, while those with shorter (3-4) or longer (8) linkers had lower affinity. elifesciences.org The inclusion of heteroatoms in the aliphatic linker, particularly in the absence of methoxy groups on the benzene rings, has been associated with higher activity against P. carinii. researchgate.netnih.gov

Introduction of Heterocyclic Moieties

A significant strategy in the development of this compound analogues has been the incorporation of heterocyclic rings. sci-hub.se This approach aims to create more conformationally restricted molecules and to explore new interactions with biological targets. irb.hrsci-hub.se Furan, pyridine, and benzimidazole are among the heterocyclic systems that have been integrated into the this compound structure, either as part of the linker or as replacements for the phenyl rings. irb.hrasm.orgnih.gov

For example, replacing the central benzene ring with a furan or pyridine dicarboxamide has led to compounds with altered biological activity and selectivity. irb.hrsci-hub.se The introduction of a furandicarboxamide core was found to increase antiproliferative activity and selectivity against certain tumor cell lines. irb.hrsci-hub.se Similarly, the synthesis of benzimidazole-pentamidine hybrids has yielded compounds with potent activity against a range of protozoa, including Trichomonas vaginalis, Giardia lamblia, and Entamoeba histolytica. nih.gov

The type of heterocyclic moiety and its point of attachment can have a profound impact on the drug's properties. For instance, in a series of dicationic substituted bis-benzimidazoles, bridging the benzimidazoles with a 2,6-pyridine linker resulted in compounds where the imidazoline-substituted analogue showed good activity against Candida albicans and Cryptococcus neoformans, while the amidine-substituted version was inactive. asm.org

Prodrug Strategies and Improved Bioavailability

A major limitation of this compound is its poor oral bioavailability, largely due to the highly basic nature of the amidine groups, which are protonated at physiological pH. unc.edu To overcome this, various prodrug strategies have been developed. Prodrugs are inactive or less active precursors that are converted to the active drug in the body. This approach aims to improve absorption and distribution. unc.eduasm.org

One of the most explored strategies involves the use of amidoximes. unc.eduasm.org Aromatic diamidoximes are less basic than the corresponding diamidines and are hypothesized to be more readily absorbed orally. asm.org Once absorbed, they are metabolically reduced by enzymes, such as the mitochondrial Amidoxime Reducing Component (mARC), to the active amidine form. asm.orggoogle.com The diamidoxime of this compound has been shown to be an orally effective anti-Pneumocystis agent. asm.org Another successful example is the prodrug DB289 (pafuramidine), an O-methylamidoxime derivative of furamidine (DB75), which has undergone clinical trials for sleeping sickness. unc.eduasm.org

Other prodrug approaches include the development of O-acyl amidoximes, which are considered double prodrugs. unc.edu These are first hydrolyzed by esterases to the amidoxime, which is then reduced to the amidine. unc.edunih.gov The diacetyldiamidoximeester of this compound is an example of this strategy, demonstrating improved lipophilicity and oral bioavailability in animal studies. google.comnih.gov Coupling this compound diamidoxime to dicarboxylic acids has also yielded prodrugs with excellent solubility and good oral bioavailability. google.com

In Vitro and In Vivo Evaluation of Analogues

The development of new this compound analogues necessitates rigorous evaluation of their biological activity through both in vitro and in vivo studies. researchgate.netasm.orgacs.org These assessments are crucial for determining the potential of a new compound as a therapeutic agent.

Comparative Efficacy against Various Pathogens

Novel this compound analogues have been tested against a wide array of pathogens to determine their spectrum of activity and comparative efficacy relative to the parent drug and other standard treatments. researchgate.netasm.orgacs.org These pathogens include protozoa such as Trypanosoma brucei rhodesiense (causing African sleeping sickness), Plasmodium falciparum (malaria), and Leishmania donovani (leishmaniasis), as well as fungi like Pneumocystis carinii and various Candida species. asm.orgacs.org

In one extensive study, 65 this compound analogues were evaluated. acs.org Several dications (compounds 32, 64, and 66) showed antitrypanosomal activity equal to or greater than the standard drug melarsoprol. acs.org Nine analogues were more active against P. falciparum than artemisinin, and eight compounds exhibited antileishmanial activity equal to or better than this compound itself. acs.org The diimidazoline 66 emerged as a particularly promising candidate with excellent in vitro activities and high selectivity against all three protozoa, coupled with significant in vivo efficacy in a mouse model of trypanosomiasis. acs.org

Analogues have also shown promise against bacterial pathogens. This compound has been found to sensitize Gram-negative bacteria to antibiotics they are typically resistant to, such as rifampicin and novobiocin. nih.gov This synergistic effect was also observed in vivo, where a combination of this compound and novobiocin successfully treated mice infected with Acinetobacter baumannii. nih.gov Furthermore, some analogues have demonstrated activity against multidrug-resistant Pseudomonas aeruginosa strains when used in combination with other antibiotics. mdpi.com

The table below summarizes the in vitro activity of selected this compound analogues against various pathogens.

Compound/AnaloguePathogenIC50/ActivityReference
Dication 32Trypanosoma brucei rhodesiense≤ 4 nM acs.org
Dication 64Trypanosoma brucei rhodesiense≤ 4 nM acs.org
Dication 66Trypanosoma brucei rhodesiense≤ 4 nM acs.org
Analogue 2Plasmodium falciparum< 6 nM acs.org
Analogue 12Leishmania donovani≤ 1.8 µM acs.org
28DAP010Trypanosoma brucei gambienseHighly active in vitro asm.orgnih.gov
Benzimidazole-pentamidine hybrid 2Giardia lamblia9-fold more potent than this compound nih.gov
Benzimidazole-pentamidine hybrid 2Entamoeba histolytica108-fold more active than this compound nih.gov

Selectivity and Cytotoxicity to Mammalian Cells

A critical aspect of developing new drugs is ensuring they are selective for the pathogen and have low toxicity to the host's cells. nih.govacs.org Therefore, a crucial step in the evaluation of this compound analogues is to assess their cytotoxicity against mammalian cell lines. nih.govacs.org The goal is to identify compounds that are highly potent against the target pathogen while exhibiting minimal effects on human cells, thus having a high selectivity index. rsc.org

Many studies have reported the synthesis of this compound analogues with significantly lower cytotoxicity than the parent compound. researchgate.netnih.govnih.gov For example, a series of 20 analogues designed as potential anti-Pneumocystis agents showed little to no cytotoxicity in mammalian cell cultures, a stark contrast to the known toxicity of this compound. nih.gov While these compounds were slightly less potent than this compound against P. carinii, their reduced toxicity makes them promising candidates for further development. nih.gov

In another study, a newly synthesized this compound derivative, WLC-4059, showed significantly less cytotoxicity compared to this compound, particularly at higher concentrations. mdpi.com This improved safety profile, combined with its efficacy, highlights the potential of rational drug design to create safer therapeutic agents. The selectivity of novel compounds for P. falciparum over human embryonic kidney (HEK293) cells has also been demonstrated, with some analogues showing selectivity indices greater than 600. rsc.org This suggests that the mechanisms of drug uptake or action in the parasite are sufficiently different from those in human cells to allow for a therapeutic window. rsc.org

The table below presents data on the cytotoxicity of selected this compound analogues.

Compound/AnalogueCell LineCytotoxicity MeasurementFindingReference
Various AnaloguesMammalian CellsCytotoxicity assaysLittle to no toxicity researchgate.netnih.govnih.gov
WLC-4059Not specifiedWST-1 assayLess toxic than this compound mdpi.com
S-MGBsHEK293IC50Selectivity indices ranging from 17 to >612.6 rsc.org
Diimidazoline 66Mammalian CellsCytotoxicity assaysHigh selectivity against T.b. rhodesiense, P. falciparum, and L. donovani acs.org

Optimization of Antiprotozoal and Antifungal Properties

Structure-activity relationship (SAR) studies have been instrumental in optimizing the antiprotozoal and antifungal properties of this compound analogues. Research has demonstrated that modifications to various parts of the this compound scaffold, including the central linker and the terminal aromatic rings, can significantly impact efficacy and selectivity against different pathogens.

A comprehensive study involving 65 this compound analogues revealed that certain structural alterations led to enhanced activity against Trypanosoma brucei rhodesiense, Plasmodium falciparum, and Leishmania donovani. acs.org For instance, dications 32 , 64 , and 66 showed antitrypanosomal activity equal to or greater than the standard drug melarsoprol. acs.org Notably, nine analogues were more potent against P. falciparum than artemisinin, and eight compounds displayed superior or equivalent antileishmanial activity compared to this compound itself. acs.org The diimidazoline analogue 66 emerged as a particularly promising candidate, exhibiting excellent in vitro activities, high selectivity, and significant in vivo efficacy in a mouse model of trypanosomiasis. acs.org

Further modifications, such as the introduction of a 2-pyridyl group in place of a phenyl ring, have also been explored. One study found that the 2-pyridyl analogue of this compound was more potent than the parent drug against both T. b. rhodesiense and P. falciparum. acs.org The development of mono-N-arylated this compound analogues has yielded compounds with sub-micromolar activity against kinetoplastid parasites, including strains resistant to this compound and diminazene. researchgate.net These analogues were also effective against Leishmania mexicana. researchgate.net

In the realm of antifungal research, twenty this compound analogues and thirty dicationic substituted bis-benzimidazoles were screened for their activity against Candida albicans and Cryptococcus neoformans. nih.gov A significant number of these compounds demonstrated potent inhibitory and fungicidal activity, with some exhibiting minimum inhibitory concentrations (MICs) comparable to amphotericin B and fluconazole. nih.gov Importantly, many of these analogues were also active against fluconazole-resistant strains and other fungal pathogens like Aspergillus fumigatus and Fusarium solani. nih.gov The presence of an arylalkyl substituent on the amidine function, however, was found to diminish antifungal activity against Pneumocystis carinii. mdpi.com

Table 1: Antiprotozoal and Antifungal Activity of Selected this compound Analogues This table is interactive. Users can sort columns by clicking on the headers.

Compound/Analogue Target Organism(s) Key Findings Reference(s)
Dication 32 Trypanosoma brucei rhodesiense Equal or greater potency than melarsoprol. acs.org
Dication 64 T. b. rhodesiense, P. falciparum, L. donovani Equal or greater potency than melarsoprol against T.b. rhodesiense. More active than artemisinin against P. falciparum. Equal or better activity than this compound against L. donovani. acs.org
Diimidazoline 66 T. b. rhodesiense, P. falciparum, L. donovani Excellent in vitro activity and high selectivity. High in vivo antitrypanosomal efficacy. acs.org
2-Pyridyl Analogue T. b. rhodesiense, P. falciparum 3- and 6-fold more potent than this compound, respectively. acs.org
Mono-N-arylated Analogues Kinetoplastid parasites, Leishmania mexicana Sub-micromolar activity, no cross-resistance in this compound-resistant strains. researchgate.net
Dicationic bis-benzimidazoles Candida albicans, Cryptococcus neoformans Potent inhibitory and fungicidal activity, comparable to amphotericin B and fluconazole. Active against fluconazole-resistant strains. nih.gov
Sulphur-containing linker analogue Cardiac IK1 channel Significantly potentiated inhibition of inward and outward current. oup.com

Evaluation for Repurposed Applications (e.g., Antibacterial, Anti-cancer)

The potential of this compound and its analogues extends beyond their traditional use, with significant research focused on repurposing these compounds for antibacterial and anti-cancer therapies.

Antibacterial Applications:

This compound has been identified as a promising agent to combat multidrug-resistant (MDR) Gram-negative bacteria, not as a standalone antibiotic, but as an adjuvant that sensitizes these pathogens to existing antibiotics. nih.govamegroups.org It effectively perturbs the Gram-negative outer membrane by interacting with lipopolysaccharide (LPS), thereby increasing the permeability to other drugs. nih.govmdpi.com This synergistic effect has been demonstrated with antibiotics typically effective only against Gram-positive bacteria, such as rifampicin, novobiocin, and erythromycin. nih.govresearchgate.net

Studies have shown that this compound in combination with rifampicin is effective against a wide range of Gram-negative pathogens in vitro, and systemic Acinetobacter baumannii infections in mice. nih.gov This combination therapy has also shown promise against MDR Pseudomonas aeruginosa strains. mdpi.com Furthermore, this compound's adjuvant activity persists in polymyxin-resistant bacteria. nih.gov The development of this compound analogues has led to the synthesis of compounds with significant enhancement of the activity of Gram-positive specific antibiotics against E. coli, K. pneumoniae, A. baumannii, and P. aeruginosa. researchgate.net

Anti-cancer Applications:

This compound has been proposed for repurposing in cancer therapy due to its ability to modulate various signaling pathways implicated in cancer progression. scienceopen.comnih.gov It has been shown to inhibit cancer cell proliferation, invasion, migration, and angiogenesis while inducing apoptosis and anti-tumor immune responses. scienceopen.comnih.gov These effects are mediated through the modulation of pathways such as PI3K/AKT, MAPK/ERK, and p53. scienceopen.comnih.govresearchgate.net

Recent studies have identified this compound as a small-molecule antagonist of the programmed death-ligand 1 (PD-L1). frontiersin.orgnih.govresearchgate.netnih.gov By binding to PD-L1, this compound can block the PD-1/PD-L1 interaction, thereby restoring T-cell activity and enhancing T-cell-mediated anti-cancer cytotoxicity. frontiersin.orgnih.govresearchgate.netnih.gov In vivo studies using a PD-L1 humanized syngeneic mouse tumor model demonstrated that this compound attenuated tumor growth and prolonged survival. frontiersin.orgnih.gov Histological analysis revealed an increased number of tumor-infiltrating lymphocytes in this compound-treated mice. frontiersin.orgnih.govresearchgate.net

Furthermore, amino analogues of this compound have demonstrated antiproliferative activity in the MCF-7 human breast cancer cell line. ptfarm.pl this compound has also been shown to inhibit the S100B-p53 interaction in glioma cells, leading to apoptosis. spandidos-publications.com

Table 2: Repurposed Applications of this compound and its Analogues This table is interactive. Users can sort columns by clicking on the headers.

Application Mechanism of Action Key Findings Reference(s)
Antibacterial Disrupts Gram-negative outer membrane via LPS interaction, sensitizing bacteria to other antibiotics. Synergistic effect with rifampicin, novobiocin, and erythromycin against MDR Gram-negative pathogens. Effective against polymyxin-resistant strains. nih.govamegroups.orgmdpi.comresearchgate.netmdpi.com
Anti-cancer Modulates signaling pathways (PI3K/AKT, MAPK/ERK, p53). Antagonist of PD-L1. Inhibits S100B-p53 interaction. Inhibits cancer cell proliferation, invasion, and migration. Induces apoptosis and anti-tumor immune response. Restores T-cell activity by blocking PD-1/PD-L1 interaction. scienceopen.comnih.govresearchgate.netfrontiersin.orgnih.govresearchgate.netnih.govptfarm.plspandidos-publications.com

Computational Approaches in Drug Design

Computational methods have become indispensable tools in the design and development of novel this compound analogues, providing insights into their structure-activity relationships and mechanisms of action.

Molecular Electrostatic Potential (MEP) Analysis

Molecular Electrostatic Potential (MEP) analysis is a computational technique used to visualize the charge distribution of a molecule and predict how it will interact with other molecules. rsdjournal.org This method has been applied to study this compound and its derivatives to identify key structural features necessary for their biological activity, particularly against Trypanosoma brucei rhodesiense. rsdjournal.orgrsdjournal.org

MEP studies help in understanding the reactive sites of the molecules and their potential interactions with biological receptors. rsdjournal.org For this compound analogues, MEP analysis has been used to guide the design of new compounds with potentially enhanced activity. rsdjournal.org The distribution of negative and neutral MEP values on the surface of molecular cavities has been shown to influence the binding of cationic drugs like this compound. rsc.org The Breneman model is often used to compute the ESP-atomic partial charges on the atoms, which are then used to reproduce the molecular electrostatic potential. rsc.orgnih.gov

Pattern Recognition Models

Pattern recognition models, such as Principal Component Analysis (PCA), Hierarchical Cluster Analysis (HCA), and Soft Independent Modeling of Class Analogy (SIMCA), are statistical methods used to classify compounds based on their structural and physicochemical properties. rsdjournal.orgscielo.brresearchgate.netscielo.br These models have been successfully employed to study a series of this compound derivatives with activity against T. b. rhodesiense. rsdjournal.org

By reducing the dimensionality of a data matrix containing various molecular descriptors, these models can classify compounds into different activity classes (e.g., more active or less active). rsdjournal.org A study on twenty-eight this compound derivatives identified that properties like the highest occupied molecular orbital (HOMO) energy, molecular volume (VOL), and the water-accessible surface area of all polar atoms (ASA_P) are crucial for constructing these classification models. rsdjournal.org The application of these models led to the identification of nine promising new compounds for synthesis and further biological evaluation. rsdjournal.org The 3D-WHIM descriptors, which capture information about the molecule's size, shape, and atom distribution, have also been used in PCA and SIMCA analyses to classify bisamidine conformations. scielo.brresearchgate.netscielo.br

Molecular Modeling and Docking Studies

Molecular modeling and docking are powerful computational techniques used to predict the binding orientation and affinity of a ligand to its target receptor. These methods have been extensively used to understand the interactions of this compound and its analogues with their biological targets, primarily the minor groove of B-DNA. ptfarm.plscielo.brnih.govnih.govbibliotekanauki.pl

Docking studies have shown that this compound analogues bind to the minor groove of DNA, with a preference for AT-rich sequences. ptfarm.pl The binding is stabilized by van der Waals and electrostatic interactions, which are considered more critical than specific hydrogen bonds. nih.gov The positive charge of the amidine groups facilitates interactions with the negatively charged phosphate backbone of DNA. ptfarm.pl

These studies have provided rationalizations for the differences in DNA-binding behavior observed among this compound analogues with varying linker chain lengths and aromatic ring substitutions. nih.gov For instance, furan-containing analogues have been shown to penetrate the minor groove more effectively and cause less structural perturbation upon binding compared to this compound. nih.gov Molecular dynamics (MD) simulations have also been used to study the stability of complexes between this compound derivatives and proteins like α1-acid glycoprotein (AGP), indicating that stable complexes are formed. nih.gov Docking studies have also been employed to investigate the interaction of this compound analogues with other targets, including the NMDA receptor and the hERG K+ channel. rsc.orgmeduniwien.ac.at

Research on Adverse Effects and Toxicity Mechanisms

Strategies for Mitigating Toxicity

Hydration Protocols

Adequate hydration is a critical strategy to mitigate certain adverse effects associated with pentamidine administration, particularly nephrotoxicity and hypotension. Patients who are dehydrated may exhibit increased susceptibility to the nephrotoxic and hypotensive effects of parenteral this compound drugs.com. Therefore, correcting dehydration prior to initiating therapy is preferable drugs.com.

Research indicates that maintaining proper fluid balance can reduce the incidence and severity of side effects, including liver or kidney dysfunction, hypertension, hypotension, hypoglycemia, and hypokalemia drugbank.com. In clinical practice, additional intravenous fluids during this compound administration have been employed as a therapeutic intervention for managing adverse events plos.org. This approach aims to support renal function and blood pressure stability, thereby potentially reducing the risk of drug accumulation in the kidneys and subsequent toxicity drugs.comoup.comwikipedia.orgccjm.org.

Table 1: Impact of Hydration on this compound-Associated Adverse Effects

Adverse Effect CategoryPotential Impact of Adequate HydrationResearch Findings / Mechanisms
Renal DysfunctionReduced incidence of acute kidney injury (AKI) and potentially, less severe AKI.This compound is primarily cleared renally, and adequate hydration helps maintain renal perfusion, potentially reducing direct tubular damage and enhancing drug clearance, though studies suggest only a small percentage of the drug is excreted unchanged via the kidneys pfizer.comoup.comnih.gov.
HypotensionDecreased frequency and severity of sudden, severe hypotension.Maintaining adequate intravascular volume supports blood pressure, counteracting this compound's direct vasodilatory effects or other mechanisms leading to hypotension drugs.compogo.canps.org.au.
HypoglycemiaPotential for reduced severity, though the primary mechanism is pancreatic beta-cell toxicity.While not directly addressing the pancreatic toxicity, good hydration helps maintain overall physiological stability, which might indirectly support metabolic regulation drugbank.comdrugs.comjwatch.orgamegroups.orghres.ca.

Dosage Adjustment Considerations

This compound exhibits complex pharmacokinetics, characterized by a long elimination half-life and significant tissue accumulation, even in individuals with normal renal function wikipedia.orgnih.govnih.gov. This accumulation can lead to increased trough concentrations with multiple dosing nih.govoup.com.

Research into dosage adjustments, particularly in the context of renal impairment, has yielded important findings. Studies have shown that renal clearance accounts for a small fraction (approximately 2.1% to 6%) of this compound's total plasma clearance pfizer.comnih.govhres.ca. Consequently, some research suggests that dosage adjustments may not be strictly necessary for patients with creatinine clearances greater than 35 mL/min nih.govoup.com. However, there is limited information on the kinetics or the full adverse effects profile of this compound in patients with severely impaired renal function (creatinine clearance <35 mL/min) pfizer.com.

Despite the low renal clearance, the drug's long half-life (ranging from 29 to 118 hours in some studies, and up to 12 days after the last dose in others) and accumulation potential suggest that lower dose regimens, while still efficacious, might be associated with reduced toxicity, especially with multiple dosing wikipedia.orgnih.govnih.govoup.com. The risk of nephrotoxicity may be higher in patients with AIDS, sometimes accompanied by severe hyperkalemia drugs.com. Therefore, careful monitoring of renal function (serum creatinine and blood urea nitrogen) and serum potassium levels is crucial, and a reduction in dosing frequency or withdrawal of therapy may be warranted if toxicity develops drugs.comnih.gov.

Table 2: Pharmacokinetic Parameters and Renal Function in this compound Administration

ParameterNormal Renal Function (Mean ± SD) nih.govnih.govRenal Impairment (CrCl 35-145 mL/min) nih.govHemodialysis Patients nih.govnih.gov
Elimination Half-Life (hr)6.22 ± 1.17 (range 29-118) nih.govnih.govNot significantly correlated with CrCl nih.govAppears not significantly affected by dialysis nih.gov
Plasma Clearance (L/hr)411 ± 55 (range 268-329) nih.govnih.govNot significantly correlated with CrCl nih.gov-
Renal Clearance (% of Plasma)2.1% - 5.0% nih.govhres.caSimilar amounts (1-4%) excreted pfizer.comNot appreciably removed pfizer.com
Drug AccumulationOccurs with daily dosing nih.govnih.govoup.comOccurs with multiple dosing nih.govoup.com-

Co-administration with Modulating Agents

The co-administration of this compound with other agents can significantly influence its toxicity profile, primarily through pharmacokinetic and pharmacodynamic interactions. Research highlights several key areas of concern:

Nephrotoxic Agents: Concurrent or sequential use of this compound with other nephrotoxic drugs, such as aminoglycosides, amphotericin B, cisplatin, foscarnet, and vancomycin, should be closely monitored or avoided if possible, as their nephrotoxic effects may be additive drugbank.comdrugs.comdrugs.comnih.govresearchgate.net. This compound's renal transport involves filtration, secretion, and passive reabsorption, and inhibition of luminal transport by other medications can increase drug accumulation in the kidney, predisposing patients to toxicity oup.com.

QTc Prolonging Agents: this compound is known to prolong the QTc interval, increasing the risk of Torsade de Pointes and other serious arrhythmias drugbank.comdrugs.commedscape.commdpi.com. Co-administration with other drugs that also prolong the QTc interval (e.g., certain antiarrhythmics, antihistamines, antipsychotics, antidepressants, antibiotics like quinolones and macrolides, and antifungals) is often contraindicated or requires careful monitoring drugbank.comnih.govmedscape.com.

Agents Affecting Glucose Metabolism: this compound can cause both hypoglycemia and hyperglycemia due to its direct cytotoxic effects on pancreatic beta cells, leading to initial insulin release and subsequent insufficient insulin secretion drugs.comdrugs.comnih.govjwatch.orgamegroups.orghres.cabmj.com. Therefore, co-administration with drugs that can also affect blood glucose levels (e.g., diuretics, insulin, oral hypoglycemic agents) requires vigilant monitoring drugbank.comdrugs.compogo.camedscape.com.

Dideoxyinosine (ddI): In animal studies, co-administration of dideoxyinosine has been shown to increase the renal clearance of this compound, suggesting a potential interaction that could alter this compound disposition oup.com. However, the clinical implications of this interaction for toxicity mitigation require further characterization.

Table 3: Drug Interaction Categories and Mechanisms with this compound

Interaction CategoryExamples of Modulating Agents (Non-Exhaustive)Mechanism of Interaction with this compoundPotential OutcomeResearch Reference
Nephrotoxic AgentsAminoglycosides, Amphotericin B, Cisplatin, Foscarnet, Vancomycin, NSAIDsAdditive nephrotoxicity; potential for altered renal disposition due to transporter inhibition.Increased risk of acute kidney injury and renal failure. drugbank.comdrugs.comdrugs.comnih.govoup.comresearchgate.net
QTc Prolonging AgentsAdagrasib, Alfuzosin, Amiodarone, Azithromycin, Moxifloxacin, PimozideAdditive QTc prolongation.Increased risk of Torsade de Pointes and arrhythmias. drugbank.comdrugs.comnih.govmedscape.commdpi.com
Agents Affecting GlucoseDiuretics, Acetylsalicylic acid, Canagliflozin, SulfonylureasExacerbation of hypoglycemia or hyperglycemia; direct pancreatic beta-cell toxicity by this compound.Severe dysglycemia (hypo- or hyperglycemia). drugbank.comdrugs.comdrugs.comjwatch.orgamegroups.orghres.cabmj.com
Dideoxyinosine (ddI)DideoxyinosineIncreased renal clearance of this compound (in rats).Potential for altered this compound disposition. oup.com

Drug Interactions and Combination Therapy Research

Pharmacokinetic and Pharmacodynamic Interactions

The interactions of pentamidine with other drugs can be categorized by their effects on its concentration in the body and the combined impact on organ systems. These interactions are critical to manage, as they can lead to either decreased therapeutic effect or increased toxicity.

The concentration of this compound in the blood can be altered by other medications, primarily through effects on its metabolic pathways.

Inhibitors of Metabolism: Co-administration with drugs that inhibit the cytochrome P450 (CYP) enzyme system, particularly CYP2C19, can lead to increased this compound levels. For instance, the metabolism of this compound can be decreased when combined with acalabrutinib, ambrisentan, amprenavir, aprepitant, armodafinil, or atazanavir. drugbank.com Similarly, etravirine, by affecting CYP2C19 metabolism, can increase this compound levels, heightening the risk of toxicity. medscape.com Celecoxib, a CYP2D6 inhibitor, may also enhance the exposure and toxicity of this compound. pdr.net

Inducers of Metabolism: Conversely, drugs that induce CYP enzymes can decrease this compound's serum concentration. Apalutamide, by affecting CYP2C19, and apremilast can increase the metabolism of this compound, potentially reducing its therapeutic efficacy. drugbank.com

Competition for Secretion: Drugs that compete for active tubular secretion in the kidneys may also increase serum concentrations of this compound. medscape.com

This compound can also influence the serum levels and clearance of other medications. It may decrease the excretion rate of a variety of drugs, leading to higher serum levels and potential for toxicity. drugbank.com Examples of drugs whose excretion may be decreased by this compound include:

Acetaminophen

Aclidinium

Aldesleukin

Allopurinol

Almasilate

Alprazolam

Amikacin

Amrinone

Ancestim

Auranofin drugbank.com

Furthermore, this compound can decrease the metabolism of other drugs, such as alfentanil, amitriptyline, apixaban, and atorvastatin, by inhibiting their metabolic pathways. drugbank.com

The co-administration of this compound with other drugs can lead to an increased risk of toxicity to various organs, most notably the kidneys and heart.

Nephrotoxicity: The risk of kidney damage is heightened when this compound is used concurrently or sequentially with other nephrotoxic agents. hres.cahres.canih.gov Caution is advised when combining this compound with drugs such as:

Aminoglycosides (e.g., amikacin, gentamicin) medscape.compdr.net

Amphotericin B hres.cahres.ca

Cisplatin pdr.nethres.cahres.ca

Foscarnet medscape.comnih.gov

Vancomycin hres.cahres.ca

Acyclovir, aceclofenac, acemetacin, alendronic acid, and antrafenine drugbank.com

Cardiotoxicity (QTc Prolongation): this compound is known to prolong the QTc interval, and this effect can be additive with other drugs that share this property, increasing the risk of serious cardiac arrhythmias like Torsade de Pointes. medscape.comnih.gov Numerous drugs are contraindicated or require close monitoring when used with this compound for this reason, including:

Antiarrhythmics: Amiodarone, disopyramide, dofetilide, dronedarone medscape.compdr.net

Antipsychotics: Amisulpride, aripiprazole, risperidone drugbank.commedscape.com

Antibiotics: Clarithromycin, erythromycin, levofloxacin, moxifloxacin medscape.compdr.net

Antifungals: Posaconazole medscape.com

Others: Alfuzosin, anagrelide, apomorphine, arsenic trioxide, artemether, citalopram, escitalopram, lapatinib, ondansetron, saquinavir, sertraline, sunitinib, and many others. drugbank.commedscape.compdr.net

Hepatotoxicity: Caution is also recommended when administering this compound with other drugs that have the potential to cause liver damage. hres.cahres.ca

Hematologic Toxicity: Similarly, co-administration with medications that can impair the hematopoietic system should be done with care. hres.cahres.ca

Hypoglycemia and Hyperglycemia: The risk of hypoglycemia can be increased when this compound is combined with acetylsalicylic acid. drugbank.com Conversely, its hypoglycemic effects may be diminished by amineptine. drugbank.com Alclometasone and amcinonide can increase the risk of hyperglycemia when combined with this compound. drugbank.com

Table 1: Drug Interactions with this compound Affecting Serum Levels and Organ Toxicity

Interacting Drug Class Specific Examples Potential Effect
CYP2C19 Inhibitors Acalabrutinib, Amprenavir, Aprepitant, Atazanavir, Etravirine Increased this compound serum levels, potential for toxicity drugbank.commedscape.com
CYP2C19 Inducers Apalutamide, Apremilast Decreased this compound serum levels, potential for reduced efficacy drugbank.com
Nephrotoxic Agents Aminoglycosides, Amphotericin B, Cisplatin, Foscarnet, Vancomycin Additive nephrotoxicity pdr.nethres.cahres.canih.gov
QTc-Prolonging Agents Amiodarone, Clarithromycin, Erythromycin, Levofloxacin, Risperidone Increased risk of cardiac arrhythmias (Torsade de Pointes) medscape.compdr.netnih.gov
Hepatotoxic Agents Not specified Additive hepatotoxicity hres.cahres.ca
Hematopoietic Impairing Agents Not specified Additive hematologic toxicity hres.cahres.ca

Interactions Affecting Clearance of Other Drugs

Synergistic Effects in Combination Therapies

Research has increasingly focused on repurposing this compound as an adjuvant in combination therapies, particularly to combat antimicrobial resistance. Its ability to disrupt the outer membrane of Gram-negative bacteria makes it a candidate for potentiating the effects of other antibiotics.

A significant area of research is the use of this compound to make Gram-negative bacteria susceptible to antibiotics that are typically only effective against Gram-positive organisms. nih.govnih.gov The mechanism is believed to involve this compound's interaction with the lipopolysaccharide (LPS) in the outer membrane of Gram-negative bacteria, which increases the membrane's permeability. mdpi.comamegroups.org This disruption allows co-administered antibiotics to gain access to their intracellular targets. nih.govmdpi.com

In Vitro and In Vivo Efficacy: Studies have demonstrated synergistic effects when this compound is combined with antibiotics like rifampicin, novobiocin, and erythromycin against a range of Gram-negative pathogens, including Acinetobacter baumannii, Klebsiella pneumoniae, and Escherichia coli. mdpi.comamegroups.orgresearchgate.net This combination has shown efficacy in mouse models of systemic A. baumannii infection. nih.govresearchgate.net

Overcoming Resistance: Notably, the adjuvant activity of this compound persists even in bacteria that have acquired resistance to polymyxins, such as colistin. nih.govamegroups.org

Combination with Linezolid: When combined with this compound, the Gram-positive-specific antibiotic linezolid becomes active against carbapenem-resistant Enterobacteriaceae (CRE). asm.org Mechanistic studies suggest this compound disrupts the outer membrane, dissipates the membrane potential, and inhibits efflux pumps, thereby increasing the intracellular concentration of linezolid. asm.org

Combination with Ciprofloxacin: The combination of this compound and ciprofloxacin has shown synergistic, bactericidal inhibition against fluoroquinolone-resistant strains of Pseudomonas aeruginosa. mdpi.com This synergy is also attributed to this compound's membrane-disrupting effects and potential inhibition of efflux pumps. mdpi.com

Combination with Carbapenems: this compound combined with imipenem or meropenem has demonstrated synergistic activity against the majority of multidrug-resistant P. aeruginosa clinical strains tested. mdpi.com

In the realm of antiprotozoal therapy, this compound has been studied in combination with other agents to improve treatment outcomes, particularly for leishmaniasis.

Combination with Allopurinol: For the treatment of diffuse cutaneous leishmaniasis (DCL) caused by Leishmania mexicana mexicana, a combination of this compound and allopurinol has been investigated. nih.gov In vitro studies observed a synergistic effect between the two drugs. nih.gov When combined with recombinant human interferon-gamma, this polychemotherapy led to rapid recovery in patients with advanced DCL, although relapse occurred after a few months. nih.gov This approach suggests a potential for reducing this compound dosage and its associated toxicity. nih.gov

Novel Drug Delivery Systems and Formulations Research

Nanoparticle-Based Delivery

The systemic administration of pentamidine is associated with significant side effects, including nephrotoxicity. To mitigate these adverse effects and enhance therapeutic efficacy, research has focused on developing nanoparticle-based drug delivery systems. These systems aim to improve drug targeting and provide sustained release, thereby increasing the drug's bioavailability and reducing its toxicity. Various nanocarriers, such as polymeric, lipidic, and inorganic nanoparticles, have been investigated for this compound delivery. nih.gov

Enhanced Efficiency and Targeted Delivery

Nanoparticles offer a promising platform for the targeted and efficient delivery of this compound. By encapsulating this compound within nanocarriers, it is possible to modify its pharmacokinetic profile and direct it to specific cells or tissues.

One approach involves the use of lipid-polymer hybrid nanoparticles. For instance, nanoparticles composed of poly(lactic-co-glycolic) acid (PLGA) and a hyaluronic acid (HA)-phospholipid conjugate have been developed. These particles, with a size below 150 nm and a high encapsulation efficiency of 90%, are designed to target cells that overexpress the CD44 receptor, a receptor for HA. unimi.itnih.gov This targeted delivery was demonstrated in vitro, where the HA-coated nanoparticles showed preferential and receptor-mediated cytotoxicity towards cancer cells with high CD44 expression. unimi.itnih.gov The presence of HA on the nanoparticle surface was shown to be crucial for this targeted effect, as confirmed by competition assays. unimi.it

Another strategy utilizes chitosan nanoparticles, which are biodegradable and biocompatible. This compound-loaded chitosan nanoparticles (PTN-CNPs) have been synthesized with a spherical shape and a size of 88 nm. msptm.org These nanoparticles demonstrated enhanced antileishmanial activity in vitro compared to free this compound, suggesting they act as a targeted drug delivery system. msptm.org The half-maximal inhibitory concentration (IC50) values of PTN-CNPs against Leishmania tropica promastigotes and amastigotes were significantly lower than those of the free drug. msptm.org

Furthermore, polymethacrylate nanoparticles have been explored for delivering this compound. These nanoparticles are taken up by macrophagic cells and localize within phagolysosomes, which can then fuse with parasitophorous vacuoles containing Leishmania parasites. nih.gov This intracellular trafficking allows for the targeted delivery of this compound to the site of infection. nih.gov

The table below summarizes the characteristics of different nanoparticle-based this compound delivery systems.

Nanoparticle TypeCore/Shell MaterialsSize (nm)Encapsulation Efficiency (%)Key Feature
Lipid-Polymer HybridPLGA / HA-DPPE< 15090CD44 receptor targeting unimi.itnih.gov
Chitosan NanoparticlesChitosan / Sodium tripolyphosphate8886Enhanced antileishmanial activity msptm.org
PolymethacrylateMethacrylic acid polymer--Intracellular delivery to macrophages nih.gov
Polycaprolactone (PCL)PCL267.58-Blood-brain barrier transport tandfonline.com
LiposomesPhosphatidylcholine119.61-Blood-brain barrier transport tandfonline.com
Hyaluronic acid/PolyarginineHyaluronic acid / Polyarginine-80High encapsulation of this compound isethionate researchgate.net

Release Kinetics and Intracellular Action

The release of this compound from nanoparticles is often pH-dependent, a feature that can be exploited for controlled drug release within specific cellular compartments. For example, this compound is bound to polymethacrylate nanoparticles through ionic interactions between the carboxylic acid groups of the polymer and the amine groups of the drug. nih.gov This interaction is sensitive to pH, with a decrease in pH leading to drug release. At a pH of 5, which is characteristic of lysosomes and parasitophorous vacuoles, up to 50% of the encapsulated this compound can be released. nih.gov

Similarly, the release of this compound from chitosan nanoparticles is sustained over time. In vitro studies have shown an initial rapid release of about 50% of the drug within the first 9 hours at pH 7.4, followed by a more gradual release, reaching approximately 92% after 36 hours. msptm.org Polycaprolactone (PCL) nanoparticles and liposomes have also been studied, releasing 12.13% and 22.21% of their this compound load, respectively, after 24 hours. tandfonline.com

Once inside the target cells, the nanoparticle-delivered this compound can exert its therapeutic effect. Ultrastructural studies have visualized the trafficking of drug-loaded polymethacrylate nanoparticles within Leishmania-infected Küpffer cells. nih.gov The nanoparticles are taken up by these phagocytic cells and are found within phagosomes that fuse with lysosomes. nih.gov These secondary lysosomes, containing the nanoparticles, then fuse with the parasitophorous vacuoles where the Leishmania amastigotes reside. nih.gov Although the nanoparticles were observed in close proximity to the parasites, direct internalization by the amastigotes was not seen. nih.gov This suggests that the released this compound is the active agent acting on the parasites within the vacuole. nih.gov

The enhanced efficacy of nanoparticle-encapsulated this compound is attributed to the higher intracellular drug concentration achieved compared to the administration of the free drug. unimi.it This increased intracellular delivery can overcome potential drug resistance mechanisms and lead to improved therapeutic outcomes. nih.gov

Aerosolized/Inhaled Formulations

Aerosolized this compound offers a method for direct delivery to the lungs, which is particularly advantageous for the prevention and treatment of Pneumocystis jiroveci pneumonia (PJP). This route of administration achieves high local drug concentrations in the bronchoalveolar lavage fluid while minimizing systemic exposure and associated side effects. wikipedia.orgnih.gov

Localized Delivery and Systemic Absorption

When administered via inhalation, this compound accumulates on the bronchoalveolar surface at concentrations significantly higher than those achieved with parenteral administration. nih.gov In one study involving AIDS patients, the mean concentration of this compound in bronchoalveolar lavage fluid 18 to 24 hours after a single 300 mg inhaled dose was 23.2 ng/mL. drugs.com

Systemic absorption of aerosolized this compound is minimal. nih.govnih.gov The mean plasma concentration immediately following inhalation has been reported to be 13.84 ng/mL, which is only 5% of the mean peak plasma concentration observed after intravenous administration. nih.govasm.org Furthermore, repeated inhalation does not lead to drug accumulation in the plasma, a phenomenon that is observed with multiple intravenous doses. nih.govasm.org Cumulative urinary excretion of this compound 24 hours after the first inhaled dose is also only 5% of that seen with intravenous administration. nih.govasm.org

The table below provides a comparison of this compound concentrations after different routes of administration.

Administration RouteSite of MeasurementMean ConcentrationTime Post-Administration
Inhaled (300 mg)Bronchoalveolar Lavage Fluid23.2 ng/mL18-24 hours drugs.com
Inhaled (4 mg/kg/day)Peak Plasma18.8 ng/mLAfter first dose drugs.com
Intravenous (4 mg/kg)Peak Plasma612 ng/mL- drugs.com
Inhaled (once-daily)Bronchoalveolar Fluid28.6 - 177.5 ng/mL24 hours nih.gov
Intravenous (low-dose)Bronchoalveolar Fluid6.05 - 21.4 ng/mL24 hours nih.gov

Pulmonary Pharmacokinetics

The pharmacokinetics of this compound in the lungs following aerosolized delivery are characterized by a long half-life. nih.gov Studies have shown that this compound can be detected in bronchoalveolar fluid for extended periods, with one patient having detectable levels 115 days after completing a two-week course of therapy. nih.govasm.org While this compound concentrations in the bronchoalveolar fluid were generally higher after two weeks of therapy compared to the first day, the difference was not statistically significant. nih.govasm.org

The deposition of aerosolized this compound in the lungs is influenced by the nebulizer system used. atsjournals.org The particle size generated by the nebulizer is a critical factor, with an ideal mass median aerodynamic diameter (MMAD) of 1 to 2 microns for optimal distribution throughout the lungs. nih.gov Jet nebulizers, such as the Respirgard II, produce particles within this ideal range. nih.gov The amount of drug deposited in the lungs has been found to be a major determinant of the resulting drug levels in pulmonary secretions. atsjournals.org

Q & A

Advanced Research Question

  • Native PAGE binding assays : Incubate pure tRNA (e.g., tRNALeu) with this compound (0–400 µM) in varying Mg²⁺ concentrations (0–5 mM). Observe electrophoretic mobility shifts; reduced migration indicates binding .
  • pH-dependent studies : Assess binding affinity at pH 5.0–8.0. Electrostatic interactions dominate in low Mg²⁺, while hydrophobic interactions prevail in high Mg²⁺ .
  • Functional assays : Couple binding studies with mitochondrial translation inhibition assays (e.g., amino acid misincorporation via radiolabeling) to validate biological impact .

How can researchers design experiments to study the impact of this compound on mitochondrial translation in eukaryotic models?

Advanced Research Question

  • Model selection : Use Leishmania mexicana or HeLa cells with intact mitochondrial networks.
  • Mitochondrial isolation : Treat cells with this compound (10–50 µM), isolate mitochondria via differential centrifugation, and quantify RNA-drug binding via qPCR or Northern blot .
  • Phenotypic assays : Measure oxygen consumption (Seahorse Analyzer) and ATP production to correlate binding with functional deficits .

What strategies are effective in elucidating this compound's inhibitory effects on human enzymes such as diamine oxidase (hDAO)?

Advanced Research Question

  • Global nonlinear regression : Fit inhibition curves (e.g., 0–2 µM this compound) to determine Kᵢ values. Use purified hDAO and substrates (e.g., histamine) in kinetic assays .
  • Competitive vs. non-competitive analysis : Vary substrate concentrations ± this compound. Lineweaver-Burk plots distinguish inhibition modes .
  • Cross-validation : Compare inhibition patterns with structurally similar inhibitors (e.g., berenil) to identify binding site specificity .

How do carbon source variations in growth media influence this compound resistance profiles in bacterial studies?

Advanced Research Question

  • Media optimization : Culture Acinetobacter baumannii in M9 minimal media with alternate carbon sources (e.g., glucose vs. succinate).
  • Disk diffusion assays : Compare zone-of-inhibition diameters under different conditions. Resistance linked to AdeAB efflux pump activity is carbon-source-dependent .
  • Transcriptomic analysis : Perform RNA-seq to identify upregulated transporters (e.g., AdeRS regulon) under selective pressure .

What are the recommended storage conditions for this compound based on its physicochemical properties?

Basic Research Question

  • Storage : Keep in airtight containers at 15–25°C, protected from humidity (hygroscopic solid).
  • Stability : Limited decomposition data; avoid prolonged exposure to light or temperatures >186°C (melting point) .

What experimental models are suitable for studying this compound's transport mechanisms across the blood-brain barrier (BBB)?

Advanced Research Question

  • In vivo models : Use P-gp knockout mice (e.g., mdr1a/mdr1b⁻/⁻) to quantify brain uptake via LC-MS. Wild-type controls assess efflux efficiency .
  • In vitro BBB models : Co-culture brain endothelial cells with astrocytes. Apply this compound (1–10 µM) and measure transendothelial electrical resistance (TEER) and permeability .

How can researchers address contradictory findings regarding this compound's primary molecular targets across different experimental systems?

Advanced Research Question

  • Systems biology approaches : Integrate proteomics (e.g., affinity purification-MS) and transcriptomics to identify context-dependent targets.
  • Dose-response validation : Replicate studies in L. mexicana (mitochondrial target) vs. mammalian cells (tRNA/rRNA) using identical drug concentrations .
  • Mechanistic redundancy analysis : Use CRISPR knockouts (e.g., mitochondrial RNA polymerase) to dissect target contributions .

What analytical techniques are employed to validate this compound's purity and stability in experimental preparations?

Basic Research Question

  • HPLC-UV/LC-MS : Quantify purity (≥99%) using C18 columns (mobile phase: acetonitrile/0.1% TFA).
  • Stability testing : Incubate stock solutions at 4°C/-20°C; monitor degradation via peak area changes over time .

Retrosynthesis Analysis

AI-Powered Synthesis Planning: Our tool employs the Template_relevance Pistachio, Template_relevance Bkms_metabolic, Template_relevance Pistachio_ringbreaker, Template_relevance Reaxys, Template_relevance Reaxys_biocatalysis model, leveraging a vast database of chemical reactions to predict feasible synthetic routes.

One-Step Synthesis Focus: Specifically designed for one-step synthesis, it provides concise and direct routes for your target compounds, streamlining the synthesis process.

Accurate Predictions: Utilizing the extensive PISTACHIO, BKMS_METABOLIC, PISTACHIO_RINGBREAKER, REAXYS, REAXYS_BIOCATALYSIS database, our tool offers high-accuracy predictions, reflecting the latest in chemical research and data.

Strategy Settings

Precursor scoring Relevance Heuristic
Min. plausibility 0.01
Model Template_relevance
Template Set Pistachio/Bkms_metabolic/Pistachio_ringbreaker/Reaxys/Reaxys_biocatalysis
Top-N result to add to graph 6

Feasible Synthetic Routes

Reactant of Route 1
Reactant of Route 1
Pentamidine
Reactant of Route 2
Pentamidine

Disclaimer and Information on In-Vitro Research Products

Please be aware that all articles and product information presented on BenchChem are intended solely for informational purposes. The products available for purchase on BenchChem are specifically designed for in-vitro studies, which are conducted outside of living organisms. In-vitro studies, derived from the Latin term "in glass," involve experiments performed in controlled laboratory settings using cells or tissues. It is important to note that these products are not categorized as medicines or drugs, and they have not received approval from the FDA for the prevention, treatment, or cure of any medical condition, ailment, or disease. We must emphasize that any form of bodily introduction of these products into humans or animals is strictly prohibited by law. It is essential to adhere to these guidelines to ensure compliance with legal and ethical standards in research and experimentation.